|
2025
|
P/S
|
Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, ca... |
|
|
P/S
|
Pharmaceutical preparations; drugs; pharmaceutical substances; peptides for pharmaceutical use; v... |
|
|
Invention
|
Immunogenic arginase 2 polypeptides.
The present invention relates to novel polypeptides, which ... |
|
|
Invention
|
Indoleamine 2,3-dioxygenase based immunotherapy.
The invention relates to the field of prophylax... |
|
2024
|
Invention
|
Pdl2 compounds.
The present invention relates to a peptide compound of PDL2 selected from a pept... |
|
|
Invention
|
Pdl1 peptides for use in cancer vaccines.
The present invention relates to a PD-L1 peptide fragm... |
|
|
Invention
|
Arginase1 polypeptides.
The present invention relates to novel polypeptides which are derived fr... |
|
|
P/S
|
Pharmaceutical preparations for the prevention and treatment of musculoskeletal, cardiovascular, ... |
|
|
P/S
|
Pharmaceutical preparations for the prevention and treatment of viral, metabolic, endocrine, musc... |
|
2023
|
Invention
|
Tgf-beta-1 vaccine. The present invention relates to novel polypeptides, which are derived from t... |
|
|
Invention
|
Cancer therapy using anti-pd-1 or anti-pd-l1 antibodies. The present invention relates to improvi... |
|
|
Invention
|
Immunogenic arginase peptides.
The present invention relates to immunogenic polypeptide fragment... |
|
|
Invention
|
Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc).
The present invention relat... |
|
|
P/S
|
Pharmaceutical preparations; drugs; pharmaceutical
substances; peptides for pharmaceutical use; ... |
|
|
Invention
|
Indoleamine 2,3-dioxygenase based immunotherapy. The invention relates to the field of prophylaxi... |
|
|
P/S
|
Scientific research for medical purposes for others relating to vaccines for the prevention and t... |
|
|
P/S
|
Vaccines for the prevention and treatment of cancer. Scientific research for medical purposes rel... |
|
|
Invention
|
Nucleotide delivery of cancer therapy.
The present invention relates to mRNAs useful in cancer t... |
|
|
Invention
|
Arginase 2 vaccine.
The present invention relates to novel polypeptides derived from Arginase 2 ... |
|
|
Invention
|
Arginase 2 vaccine. The present invention relates to novel polypeptides derived from Arginase 2 (... |
|
|
Invention
|
Nucleotide delivery of cancer therapy. The present invention relates to mRNAs useful in cancer th... |
|
2022
|
Invention
|
Pdl2 compounds. The present invention relates to a peptide compound of PDL2 selected from a pepti... |
|
|
Invention
|
Pdl1 peptides for use in cancer vaccines. The present invention relates to a PD-L1 peptide fragme... |
|
|
Invention
|
Indoleamine 2,3-dioxygenase based immunotherapy. The present invention relates to the field of pr... |
|
|
Invention
|
Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof. The present ... |
|
|
Invention
|
Indoleamine 2,3-dioxygenase based immunotherapy.
The present invention relates to the field of p... |
|
|
Invention
|
Vaccine compositions comprising c—c motif chemokine 22 (ccl22) or fragments thereof. The present ... |
|
2021
|
Invention
|
Combination therapy for cancer.
The present invention relates to a method for the prevention or ... |
|
|
Invention
|
Combination therapy for cancer.
The present disclosure relates to the field of cancer treatment ... |
|
|
Invention
|
Combination therapy for cancer. The present disclosure relates to the field of cancer treatment a... |
|
2020
|
Invention
|
Immunogenic arginase peptides. The present invention relates to immunogenic polypeptide fragments... |
|
|
Invention
|
Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof. The invention re... |
|
|
Invention
|
Tgf-beta vaccine.
The present invention relates to novel polypeptides derived from TGFb1. The in... |
|
|
Invention
|
Tgf-beta vaccine. The present invention relates to novel polypeptides derived from TGFb1. The inv... |
|
2019
|
Invention
|
Immunogenic arginase 2 polypeptides. The present invention relates to novel polypeptides, which a... |
|
|
Invention
|
Arginase1 polypeptides. The present invention relates to novel polypeptides, which are derived fr... |
|
2018
|
Invention
|
Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc). The present invention relate... |
|
|
P/S
|
[ Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, ... |
|
2017
|
Invention
|
New pdl2 compounds.
The present invention relates to a peptide compound of PDL2 selected from a ... |
|
|
Invention
|
Calr and jak2 vaccine compositions.
The present disclosure relates to CALR and JAK2 as novel T c... |
|
|
Invention
|
Calr and jak2 vaccine compositions. The present disclosure relates to CALR and JAK2 as novel T ce... |
|
|
Invention
|
Combination therapy against cancer.
The present invention relates to a method for the prevention... |
|
|
Invention
|
Combination therapy against cancer. The present invention relates to a method for the prevention ... |
|
2012
|
Invention
|
Pd-l1 based immunotherapy. The present invention relates to the field of prophylaxis and therapy ... |
